Cancer Investigation

Cancer Investigation is an international peer-reviewed oncology journal founded in 1983, and it publishes clinical and translational work drawn from across the whole of cancer medicine.《癌症调查》是一份国际同行评议的肿瘤学期刊，1983 年创刊，刊载取自整个肿瘤学领域的临床与转化研究。

Its 2025 impact factor stands at 2.2 with a five-year figure of 1.9, and the title sits in the third quartile of the oncology category of the science citation index expanded, with a CiteScore of 3.7.该刊 2025 年影响因子为 2.2，五年影响因子 1.9，在科学引文索引扩展版的肿瘤学类目中列第三区，CiteScore 为 3.7。

Scope

• Clinical studies lie at the centre of the remit, running from early phase work through to phase III and IV trials, together with observational studies of good quality and systematic reviews.临床研究处于收稿范围的核心，从早期试验一路延伸到 III 期与 IV 期试验，高质量观察性研究与系统综述同样在列。

• Translational laboratory work and biomarker studies carried out on clinical samples count as well, especially where the findings are tied to clinical outcomes.以临床样本为基础的转化实验室研究与生物标志物研究也在其列，尤其是结果与临床结局相联系的那一类。

• Rare tumors have their own place, alongside early precision oncology and the genomic medicine that supports it.罕见肿瘤自有其位置，早期精准肿瘤学与支撑它的基因组医学同样被接纳。

• Supportive care and survivorship carry real weight in the scope, including studies that take quality of life and patient reported outcomes into account.支持性治疗与生存者照护在收稿范围中占有相当分量，纳入生活质量与患者报告结局的研究也在其中。

• Health services and outcomes research falls within it too, as do studies of the methodology used in cancer research itself.卫生服务与结局研究属于这个范围，癌症研究本身所用方法学的研究同样被涵盖。

• Cancer economics, health equities and cancer policy are named subjects, and their presence widens the journal well beyond the consulting room.癌症经济学、健康公平与癌症政策被列为选题，它们的出现使这份刊物的视野越出诊室。

• The evaluation of new technologies and their potential to change clinical cancer research, diagnosis and treatment is also invited.新技术及其革新临床癌症研究、诊断与治疗潜力的评估同样受到欢迎。

• A distinctive strand of the journal is its How I Treat reviews, in which a working clinician sets out personal practice for a hard decision.该刊有一道别具一格的栏目，即 How I Treat 综述，由一线临床医生讲述自己在艰难抉择中的处理方式。

• Conference proceedings are published, as are Pro and Con discussion pieces in which two writers take opposite sides of a contested question.会议论文集得到发表，正反方讨论文章同样常见，两篇文章就一个有争议的问题各执一词。

• Articles on the Art of Medicine and on Mentorship and Leadership address trainees and young investigators directly.探讨医学艺术以及导师与领导力的文章直接面向培训中的医生与青年研究者。

• Beyond original clinical and translational papers, novel translational studies that bridge the gap between the laboratory and the clinic are considered on their own terms.除原创的临床与转化论文之外，弥合实验室与诊室之间落差的转化研究也会得到单独考虑。

• The stated purpose is to give researchers and clinicians a comprehensive account of how far the field has advanced, and a broad background of dependable information for the decisions that have to be made.该刊自述的宗旨，是为研究者与临床医生提供肿瘤学进展的全面综述，并提供作出决策所需的可靠背景资料。

• The editors call their platform nimble and cutting edge, spanning the spectrum of oncology and the parts of it that change quickly.编辑把这份刊物称作灵活而前沿的平台，覆盖肿瘤学的整个谱系以及其中变化最快的部分。

• Leading clinicians and research scientists edit the title, so both laboratory findings and the decisions they touch are expected to appear in its pages.该刊由优秀的临床医生与研究科学家担任编辑，实验室结果以及它们所牵动的决策，按理都应在刊内出现。

History

• The journal was founded in New York in 1983, and the first volume appeared under the Marcel Dekker imprint.该刊 1983 年在纽约创办，第一卷以 Marcel Dekker 的刊头出版。

• The title has never been renamed, and both MEDLINE and PubMed carry its coverage continuously from volume 1 number 1 in 1983 onwards.这份刊物的题名从未更改，MEDLINE 与 PubMed 的收录自 1983 年第 1 卷第 1 期起连绵不断。

• For more than three decades the journal was produced under that Dekker masthead, with the imprint reading New York.此后三十余年间，该刊一直由 Dekker 的刊头制作，刊头标注的出版地是纽约。

• From 2015 the imprint reads Abingdon, Oxford with Taylor & Francis, and the publisher of record is Informa UK.自 2015 年起，刊头改为英国牛津郡阿宾登的 Taylor & Francis，登记出版者为 Informa UK。

• Since 2005 the journal has appeared eight times a year, a schedule the catalog record of the title continues to report.自 2005 年起该刊每年出八期，这份刊物的编目记录至今仍照此登记。

• Scopus has covered the journal without a break from 1983 onwards, and further abstracting and index services joined it over the decades.Scopus 自 1983 年起连续收录这份刊物，其后数十年间又有更多文摘与索引服务陆续加入。

• The journal moved into a hybrid open access arrangement, joining the open select programme of the publisher so that authors may choose gold open access for an article.该刊转向混合开放获取模式，加入出版方的开放获取出版计划，作者可以选择以金色开放获取方式发表文章。

• An accelerated publication service lets an accepted article appear online within three to five weeks of submission, once peer review has been completed.该刊设有加速出版服务，经同行评审通过的文章可在投稿后三到五周内先行上网。

• Usage runs at around one hundred thousand downloads and views a year, and the median time to a first decision is three days, while a first post-review decision takes forty-five days and online publication follows acceptance by eighteen days.该刊的年度下载与浏览量在十万次上下，投稿至首次决定的中位时间为三天，评审后首次决定需四十五天，录用至上网相隔十八天。

• The impact factor has moved unevenly over the last five years, from 2.176 in 2021 and 2.368 in 2022 down to 1.8 in 2023 and 1.9 in 2024, and back to 2.2 in 2025.该刊的影响因子在近五年间起伏不定，2021 年为 2.176，2022 年 2.368，2023 年落到 1.8，2024 年 1.9，2025 年回到 2.2。

• Alongside that, the CiteScore for 2025 reached 3.7 and the SNIP stood at 0.495, both computed on the Scopus record of the journal.与此并行，2025 年的 CiteScore 达到 3.7，SNIP 为 0.495，这两项指标都基于 Scopus 的记录计算。

• An earlier description of the title stressed its departmentalized sections, which reported on more than thirty subject categories and gave clinicians a route into the wider field.该刊早期的一份说明强调其分科编辑部的做法，这些部门覆盖三十多个专题类别，为临床医生提供了通往更宽领域的路径。

Editors

• The editor-in-chief is Alexander Birbrair of the University of Wisconsin-Madison, whose own work on macrophages and tumor associated inflammation places him on the laboratory side of oncology.主编为威斯康星大学麦迪逊分校的（Alexander Birbrair），他关于巨噬细胞与肿瘤相关炎症的研究使其位于肿瘤学的实验室一侧。

• Six associate editors support him, among them Andrea Anampa-Guzman of the Mayo Clinic, Cristiane Bergerot of the cancer centre in Brasilia, and Dechao Feng of the Zhejiang Provincial People's Hospital.六位副主编襄助其事，其中有梅奥诊所的（Andrea Anampa-Guzman）、巴西利亚癌症中心的（Cristiane Bergerot），以及浙江省人民医院的（Dechao Feng）。

• The remaining associate editors are Manoj Kumar Kashyap of Parul University in Goa, Nicole Kuderer of the Advanced Cancer Research Group in Seattle, and Fawzi Abu Rous of the Henry Ford Cancer Center.其余副主编为果阿 Parul 大学的（Manoj Kumar Kashyap）、西雅图 Advanced Cancer Research Group 的（Nicole Kuderer），以及亨利福特癌症中心的（Fawzi Abu Rous）。

• A board of twenty-six members sits below them, drawn for the most part from the United States, with Volker Diehl of a clinic for internal medicine in Germany and Le Son Tran of the Medical Genetics Institute in Vietnam among them.其下设二十六人编委，多数来自美国，其中德国一所内科诊所的（Volker Diehl）与越南医学遗传学研究所的（Le Son Tran）位列其中。

• Names familiar on the United States scene include Robert C. Bast of the MD Anderson Cancer Center, Harold J. Burstein of the Dana-Farber Cancer Institute, Barbara Burtness of Fox Chase, and Nancy E. Davidson of the Sidney Kimmel Cancer Center at Johns Hopkins.美国方面的名字包括 MD Anderson 癌症中心的（Robert C. Bast）、Dana-Farber 癌症研究所的（Harold J. Burstein）、Fox Chase 癌症中心的（Barbara Burtness），以及约翰斯·霍普金斯大学 Sidney Kimmel 癌症中心的（Nancy E. Davidson）。

• Stuart Grossman of the Johns Hopkins Oncology Center, David Ilson of Memorial Sloan Kettering, Jane Liesveld and Jonathan W. Friedberg of the University of Rochester, and David C. Dale of the University of Washington also serve.约翰斯·霍普金斯肿瘤中心的（Stuart Grossman）、纪念斯隆凯特琳癌症中心的（David Ilson）、罗切斯特大学的（Jane Liesveld）与（Jonathan W. Friedberg），以及华盛顿大学的（David C. Dale）也在其列。

• Population and health services perspectives come from Zuo-Feng Zhang of the UCLA School of Public Health, Michael Kattan of the Cleveland Clinic and Alfred Neugut of Columbia.人群与卫生服务方面的视角来自加州大学洛杉矶分校公共卫生学院的（Zuo-Feng Zhang）、克利夫兰诊所的（Michael Kattan），以及哥伦比亚大学的（Alfred Neugut）。

• The publisher is recruiting a co-editor-in-chief, with applications closing on 21 November 2026 and the appointment starting in December 2026 or January 2027, to lead and manage the basic and translational research submitted to the journal, and associate editors are being sought at the same time.出版方正在招募一位共同主编，申请截止日期为 2026 年 11 月 21 日，任职自 2026 年 12 月或 2027 年 1 月起，负责领导并管理投给该刊的基础与转化研究，副主编也在同时招募之中。

• Submissions run through a single anonymized peer review policy, under which the editor-in-chief takes the final decision on acceptance, revision or rejection.稿件采用单一匿名评审政策，主编对录用、退修或退稿作最后决定。

• The editors work to the ethics guidance of the Committee on Publication Ethics, and the journal pledges to diversity, equity and inclusion in its editorial team and in its decision making.编辑依循出版伦理委员会的伦理指引行事，该刊承诺在编辑团队与决策过程中实现多元、公平与包容。

• The classes of article it takes are named explicitly: research articles, reviews, commentaries, brief reports, letters to the editor, How I Treat articles, conference proceedings and discussion pieces.该刊列明所收稿件的类别，即研究论文、综述、评论、简要报告、致编辑者的信、How I Treat 文章、会议论文集与讨论文章。

• Open access is optional rather than compulsory, and an author who chooses it may be asked for an article publishing charge, while an author who does not pays nothing at all.开放获取属于可选而非必选项，选择开放的作者可能被要求支付文章出版费，不选择的作者则分文不付。

• Institutional agreements and memberships with the publisher can bring the charge down or remove it, and the acceptance rate published by the journal stands at six per cent.与出版方之间的机构协议与会员资格可以减免或免除这项费用，该刊公布的录用率为百分之六。

• The readership is made up above all of oncologists and clinical investigators, who want a dependable account of the parts of the field that lie beyond their own practice.该刊的读者以肿瘤科医生与临床研究者为主，他们需要一份可信的综述，覆盖自己业务之外的那些肿瘤学分支。